论文部分内容阅读
目的:探讨AFP-L3和PIVKA-Ⅱ在原发性肝癌(HCC)诊断中的价值。方法:应用微量离心柱法分离检测小扁豆凝集素结合型AFP_L3百分含量(AFP-L3%),PIVKA-Ⅱ用电化学发光免疫分析试剂盒检测。结果:肿瘤标志物的判断标准为:AFP-L3%≥10%为阳性,AFP>10ng/ml为阳性,PIVKA-Ⅱ>40mAU/ml为阳性。在慢性肝病组中,AFP》20ng/mL占10.2%,HCC组中则占64.8%。AFP、AFP-L3和PIVKA-Ⅱ在HCC组都明显高于慢性肝病组,差异存在统计学意义(P<0.001)。结论:联合测定AFP-L3和PIVKA-Ⅱ可有效提高HCC的诊断价值。
Objective: To investigate the value of AFP-L3 and PIVKA-Ⅱ in the diagnosis of primary liver cancer (HCC). Methods: The percentage of lentiform lectin-bound AFP_L3 (AFP-L3%) was detected by micro-centrifugation column method. PIVKA-Ⅱ was detected by electrochemiluminescence immunoassay kit. Results: The diagnostic criteria of tumor markers were: positive for AFP-L3% ≥10%, positive for AFP> 10ng / ml and positive for PIVKA-Ⅱ> 40mAU / ml. In the chronic liver disease group, AFP "20 ng / mL accounted for 10.2%, HCC group accounted for 64.8%. AFP, AFP-L3 and PIVKA-Ⅱ in HCC group were significantly higher than those in chronic liver disease group, the difference was statistically significant (P <0.001). Conclusion: Combined determination of AFP-L3 and PIVKA-Ⅱ can effectively improve the diagnostic value of HCC.